Literature DB >> 1832236

Hepatitis B: evolving epidemiology and implications for control.

H S Margolis1, M J Alter, S C Hadler.   

Abstract

Control and the possible elimination of transmission of HBV infection is possible with the appropriate use of hepatitis B vaccines. The prevention of chronic HBV infection has the potential of reducing the association burden of chronic liver disease and primary hepatocellular carcinoma. Worldwide, strategies for the effective use of hepatitis B vaccine have been developed and are being implemented in those areas where childhood transmission is the predominant source of chronic HBV infections. However, in the United States and other areas with "low" rates of HBV infection, current vaccination strategies have not been effective and have not fully taken into account the multifaceted epidemiology of HBV infection in those areas. Unfortunately, the majority of infections occur among adults who have been the most difficult to access, who acquire infection before they realize they are at risk, and where the changing epidemiology of HBV infections among the various risk groups only emphasizes the problems of vaccine delivery. In addition, the majority of persons receiving vaccine as a result of the current strategy to immunize adult high-risk groups have been persons who acquire HBV infection through occupational exposure, a group that accounted for no more than 5% of cases even before vaccine was introduced. The failure of the current immunization strategy to prevent a disease with significant health care and economic consequences is beginning to cause a reevaluation of this approach. A comprehensive approach to eliminating HBV transmission must address infections acquired during early childhood as well as those acquired by teenagers and adults.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832236     DOI: 10.1055/s-2008-1040427

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  62 in total

1.  Hepatitis B.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-12

2.  Prevalence of hepatitis A, B and C in the Flemish population.

Authors:  M Beutels; P Van Damme; W Aelvoet; J Desmyter; F Dondeyne; C Goilav; R Mak; L Muylle; D Pierard; A Stroobant; F Van Loock; P Waumans; R Vranckx
Journal:  Eur J Epidemiol       Date:  1997-04       Impact factor: 8.082

3.  Hepatitis B prevention and control: Lessons from the East and the West.

Authors:  Monica C Robotin
Journal:  World J Hepatol       Date:  2011-02-27

4.  Current status of antiviral therapy for hepatitis B.

Authors:  Daryl T-Y Lau; Wissam Bleibel
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

5.  Inadequate hepatitis B vaccination of adolescents and adults at an urban community health center.

Authors:  J Sharfstein; P H Wise
Journal:  J Natl Med Assoc       Date:  1997-02       Impact factor: 1.798

6.  Epidemiology of hepatitis B virus infection in Albania.

Authors:  Bashkim Resuli; Skerdi Prifti; Bledar Kraja; Tatjana Nurka; Mimoza Basho; Edita Sadiku
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

Review 7.  Is hemodialysis a reason for unresponsiveness to hepatitis B vaccine? Hepatitis B virus and dialysis therapy.

Authors:  Dede Sit; Bennur Esen; Ahmet Engin Atay; Hasan Kayabaşı
Journal:  World J Hepatol       Date:  2015-04-18

8.  Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.

Authors:  L Benvegnù; M Gios; S Boccato; A Alberti
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

9.  Prevalence of hepatitis virus infections in Albanian refugees.

Authors:  T Santantonio; S Lo Caputo; C Germinario; S Squarcione; D Greco; V Laddago; G Pastore
Journal:  Eur J Epidemiol       Date:  1993-09       Impact factor: 8.082

10.  Chronic hepatitis B infection in Canada.

Authors:  G Y Minuk; J Uhanova
Journal:  Can J Infect Dis       Date:  2001-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.